Business Wire

NY-BORN

21.4.2021 15:14:06 CEST | Business Wire | Press release

Share
BORN and Alkeon Bolster Leadership Team with the Appointment of Stewart Mancey as Director of E-Concession & Retail Partners

Total global e-commerce sales represent over $25 trillion in value today, with B2B e-commerce global merchandise value representing more than $12 trillion (Statista). With close to 2 billion websites online as of January 2021, the process of navigating products and determining quality sources can be an arduous, time-consuming, and sometimes impossible task. With billions of individual products and brands represented online and the number of products only increasing by the minute, the importance of curation becomes a critical expertise to support digital transactions. Layer in the changing ways consumers make purchase decisions, including assessing sustainability, integrity, and purpose, and the importance of product strategy is perhaps more vital than ever.

The product curation process creates bespoke collections that appeal to specific demographics and niche customer groups. Modern product curation leverages customer segmentation data and purchase behavior information, followed by personalization techniques to drive product engagement and understanding, create supplemental content around products and ultimately increase transaction value. Today, BORN and Alkeon announce industry veteran Stewart Mancey as Director of E-Concession & Retail Partners, joining a deep bench of global experts from multiple categories. As Director of E-Concession & Retail Partners, Stewart will work closely with Pierre Sapin (Chief Partnership Officer), Brendan Wypich (Chief Design & Product Officer), and Jean-Christophe Chopin (CEO and Founder of BORN and former ex-Verisign and *ETrade EU founder) . Mancey will work with brands and retailers on both Alkeon and BORN. His prestigious training at Harrods and knowledge of the creativity behind each retailer will lead BORN to curate purpose-led lifestyle brands using the filters of integrity, functionality, and desirability.

Stewart states, “Twenty years at Harrods has given me a wonderful experience, fabulous industry contacts, and a deep understanding of the power of curation across multiple categories. As Head of Curation for BORN and Alkeon, I’ll guide the product strategy for both, carefully curating across multiple dimensions that reflect today’s buying priorities and creating the ideal mix representing a cross-section of the best products and companies in the world. We want to take a load of sifting off of buyers and consumers and allow them to experience best-in-class product discovery powered by machine learning, delivered in a personalized experience and a beautiful environment that leverages the latest in technology.”

Stewart started his successful buying career at Harrods when he moved from the shop floor in 2003, working through the buying office in Women’s Superbrands before becoming Buyer of Eveningwear, Armani, and Ralph Lauren after three years. He eventually moved over to Menswear in 2007, where he was Senior Buyer for Men’s Superbrands & Tailoring, overseeing over £10m in renovations and delivering strong growth throughout his four years. In 2011, Stewart added the title of Head of Buying for Sports and managed the London Olympic strategy for Harrods, along with an additional £5m renovation. In 2013, Stewart took over Head of Buying for Furniture, Technology, and Toys and increased his remit in 2017 to include Homewares. After 21 incredibly successful years with Harrods, Stewart today joins BORN and its B2B extension Alkeon. Stewart will be a key player in the vital balance between designed technology and brand culture within both BORN and Alkeon’s market networks.

CEO Jean-Christophe Chopin states, “ Our ambition across BORN and Alkeon is to transform the B2B and B2C supply chains, reimagining discovery, transaction, and connection for both communities. Stewart adds critical and unique expertise to our executive leadership, which is a collection of the best minds in curation, commerce, community, and content. Stewart will contribute his years of knowledge of culture and brands, his deep understanding of the chains of commerce across multiple categories, his leading editorial expertise, and his unmatched Rolodex of brands and creators. We are delighted to have him.”

About BORN:

BORN is a holding company specializing in digital, data-led solutions to optimize retail and wholesale supply chains and reimagine discovery and transactions online. BORN owns Alkeon, a suite of B2B solutions and software products that facilitate digital transformation, as well as BORN.com, a platform that connects a global network of design-led brands and retailers. BORN has also curated and hosted the BORN Awards for 10 years in celebration of purpose led products and creativity. BORN is led by CEO Jean-Christophe Chopin, ex-founder of *ETrade EU and Verisign EU.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release

Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release

Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release

OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye